1. Meningitis B

Introduction

Meningitis B (MenB) refers to meningitis caused by Neisseria meningitidis serogroup B, one of several strains (A, B, C, W, Y, and others) of the meningococcal bacterium. It is a serious and potentially life-threatening infection that causes inflammation of the meninges, the protective membranes surrounding the brain and spinal cord.

The meninges are three protective, membranous layers, the dura mater, arachnoid mater, and pia mater that envelop the brain and spinal cord. Their primary functions are to provide structural support, cushion the central nervous system with cerebrospinal fluid, and support vascular structures. Inflammation of these membranes causes meningitis, a serious condition characterised by fever, headache, and neck stiffness.

Although meningitis B can affect anyone, it occurs most frequently in infants, young children, adolescents, and young adults. Prompt recognition and treatment are crucial, as the disease can progress rapidly.

This document is structured in three main parts:

  • The first part provides a comprehensive overview of meningitis B, including its causes, pathophysiology, symptoms, diagnosis, treatment, prevention, and prognosis.
  • The second part examines the immunological mechanism of the MenB vaccine and contrasts biological and clinical differences between serogroup B and other meningococcal serogroups (A, C, W, Y).
  • The third part summarises and analyses a key study, “Single‑dose oral ciprofloxacin prophylaxis as a response to a meningococcal meningitis epidemic in the African meningitis belt” (Coldiron ME et al., 2018), highlighting its validated methods, principal findings, and potential application to the UK context.

Causes and Transmission

The causative organism, Neisseria meningitidis serogroup B, is a Gram-negative diplococcus. It is carried harmlessly in the nasopharynx (the back of the nose and throat) of approximately 10% of healthy individuals. Gram-negative diplococci are spherical bacteria that appear in pairs and stain pink. Key pathogenic examples include Neisseria meningitidis, Neisseria gonorrhoeae, and Moraxella catarrhalis, which cause meningitis, gonorrhea, and respiratory infections, respectively. These bacteria are typically aerobic, non-motile, and oxidase-positive.

Transmission occurs through:

  • Respiratory droplets (e.g., coughing, sneezing).
  • Close or prolonged contact, such as living in the same household, kissing, or sharing utensils.

Most carriers remain asymptomatic, but in some individuals the bacteria invade the bloodstream and cross the blood-brain barrier, leading to meningitis or septicaemia (blood poisoning).

Pathophysiology

Once N. meningitidis breaches the mucosal barrier, it enters the bloodstream and may:

  • Proliferate in the blood, releasing endotoxins that trigger a severe inflammatory response.
  • Cross the blood-brain barrier, causing inflammation of the meninges.
  • Damage blood vessels, leading to disseminated intravascular coagulation, tissue necrosis, and multi-organ failure in severe cases.

The immune response to the bacterial endotoxin is responsible for much of the tissue injury seen in meningococcal disease.

Symptoms

Symptoms can develop suddenly and may vary with age. Early signs often resemble those of a viral illness but can progress rapidly.

Common symptoms include:

  • Severe headache
  • Stiff neck
  • High fever
  • Nausea and vomiting
  • Sensitivity to light (photophobia)
  • Drowsiness or confusion
  • Seizures in some cases

In infants and young children, symptoms may be less specific:

  • Poor feeding or refusal to eat
  • Irritability or unusual crying
  • Bulging fontanelle (soft spot on the head)
  • Floppy or unresponsive appearance

Meningococcal septicaemia may occur with or without meningitis, presenting with:

  • Cold hands and feet
  • Rapid breathing
  • Muscle or joint pain
  • Pale or mottled skin
  • A non-blanching rash (does not fade when pressed with a glass), a medical emergency

Diagnosis

Prompt diagnosis is essential. Investigations may include:

  • Clinical assessment, recognising characteristic symptoms and signs.
  • Blood tests, including full blood count, inflammatory markers, and blood cultures.
  • Lumbar puncture, analysis of cerebrospinal fluid (CSF) for bacteria, white cells, glucose, and protein levels.
  • Polymerase chain reaction (PCR), detects meningococcal DNA in blood or CSF.
  • Imaging (CT or MRI), occasionally used to exclude other causes or complications before lumbar puncture.

Treatment

Meningitis B is a medical emergency. Management typically involves:

  • Immediate intravenous antibiotics, usually a third-generation cephalosporin such as ceftriaxone or cefotaxime.
    • In community settings, benzylpenicillin may be given before hospital transfer if meningococcal disease is suspected.
  • Supportive care, including oxygen, intravenous fluids, and management of shock or raised intracranial pressure.
  • Intensive care, may be required for severe cases, particularly with septicaemia or organ failure.
  • Prophylaxis for close contacts, short courses of antibiotics (e.g., rifampicin, ciprofloxacin, or ceftriaxone) to eradicate carriage and prevent secondary cases.

Prevention

Vaccination

The most effective preventive measure is immunisation:

  • The MenB vaccine (e.g., Bexsero®) protects against serogroup B meningococcal infection.
  • In the UK, it is part of the routine NHS childhood immunisation schedule, offered to:
    • Infants at 8 weeks, 16 weeks, and 1 year of age.
    • Certain high-risk groups (e.g., individuals with asplenia or complement deficiencies).

Other meningococcal vaccines (MenACWY) protect against serogroups A, C, W, and Y.

Public health measures

  • Early recognition and treatment of cases.
  • Notification to public health authorities for contact tracing.
  • Education about symptoms and the importance of seeking urgent medical help.

Dissemination of medical diagnosis

Strategies and Channels:

  • Targeted Distribution: Dissemination is not merely publishing; it is the planned, active sharing of information to specific audiences, including policymakers, clinicians, and patients.
  • The “3 P’s”: Key external dissemination methods are often described as Papers (journals), Posters, and Presentations.
  • Digital and Social Media: Increasingly, scientific information is shared via social media (SoMe), preprints, and press releases to increase speed and accessibility.
  • Tailored Approaches: Effective dissemination requires tailoring messages to the target audience (e.g., using non-technical language for patients)

Prognosis

With prompt treatment, most people recover fully. However, meningitis B remains a serious disease with potential complications, including:

  • Hearing loss
  • Neurological impairment (e.g., seizures, learning difficulties)
  • Limb amputation or scarring due to septicaemia
  • Psychological effects such as post-traumatic stress

The mortality rate in treated cases is approximately 5–10%, but can be higher if diagnosis or treatment is delayed.

Summary

Meningitis B is a rapidly progressive bacterial infection caused by Neisseria meningitidis serogroup B. It leads to inflammation of the meninges and can cause life-threatening septicaemia. Early recognition, urgent antibiotic therapy, and supportive care are vital. Vaccination has significantly reduced incidence in countries where it is routinely offered, representing a major public health success.

2. How does the MenB vaccine work immunologically and the differences between meningitis B and other meningococcal serogroups ?

Let us consider both aspects: first, the immunological mechanism of the MenB vaccine, and then the biological and clinical distinctions between serogroup B and other major meningococcal serogroups (A, C, W, Y).

Immunological Mechanism of the MenB Vaccine

Antigenic composition

Unlike the polysaccharide-based vaccines used for other meningococcal serogroups, the MenB vaccines (e.g. 4CMenB [Bexsero®] and rLP2086 [Trumenba®]) are protein-based. This is because the serogroup B polysaccharide capsule is composed of α(2→8)-linked polysialic acid, which is structurally similar to human neural cell adhesion molecules. Consequently, it is poorly immunogenic and raises concerns about potential autoimmunity if used as a vaccine antigen.

To overcome this, MenB vaccines use subcapsular outer-membrane proteins identified through reverse vaccinology. The main components of 4CMenB are:

  • Factor H binding protein (fHbp), binds human factor H to inhibit complement activation on the bacterial surface; antibodies against fHbp block this evasion mechanism.
  • Neisserial adhesin A (NadA), mediates adhesion and invasion of epithelial cells.
  • Neisserial heparin-binding antigen (NHBA), contributes to serum resistance and epithelial adherence.
  • Outer membrane vesicles (OMVs) containing PorA P1.4, provide additional strain-specific antigens and enhance immunogenicity.

Immune response pathways

  • Antigen presentation: After intramuscular administration, protein antigens are taken up by antigen-presenting cells (APCs) such as dendritic cells.
  • T-dependent activation: Peptide fragments are presented on MHC class II molecules to CD4⁺ T helper cells, which provide co-stimulatory signals to B cells.
  • B-cell differentiation: Activated B cells undergo class switching (predominantly to IgG) and affinity maturation within germinal centres.
  • Effector mechanisms: The resulting antibodies are bactericidal, they fix complement (via the classical pathway) and promote opsonophagocytosis.
  • Immunological memory: Memory B cells and long-lived plasma cells confer sustained protection and a rapid anamnestic response upon re-exposure.

Correlate of protection

Protection is assessed by the serum bactericidal antibody (SBA) assay using human complement. A fourfold rise in SBA titre or an SBA ≥1:4 is considered protective. Because of antigenic diversity among MenB strains, cross-protection depends on the degree of antigenic match between vaccine components and circulating isolates.

Biological and Clinical Differences Between Serogroup B and Other Serogroups (A, C, W, Y)

Feature Serogroup B Serogroups A, C, W, Y
Capsular composition Polysialic acid (α2→8), poorly immunogenic, mimics neural tissue Distinct polysaccharides (e.g. A: N-acetyl mannosamine phosphate; C: sialic acid α2→9; W/Y: sialic acid with different linkages), immunogenic
Vaccine type Protein-based (MenB) Polysaccharide, protein conjugate vaccines (MenACWY)
Mechanism of protection Antibodies to surface proteins (fHbp, NadA, NHBA, PorA) mediate complement-dependent killing Antibodies to capsular polysaccharides mediate complement-dependent killing
Age distribution Highest incidence in infants and young children; also adolescents Broader age range; outbreaks often in adolescents, young adults, or specific geographic regions
Epidemiology Endemic in many high-income countries; sporadic outbreaks Serogroup A historically caused large epidemics in sub-Saharan Africa; C, W, Y more prevalent elsewhere
Cross-protection Limited due to antigenic heterogeneity Conjugate vaccines provide broad coverage against included serogroups

Epidemiological and Clinical Relevance

  • Serogroup B remains a leading cause of invasive meningococcal disease (IMD) in Europe, Australasia, and parts of the Americas, particularly in infants under one year.
  • Serogroups A, C, W, Y are more geographically variable; for instance, serogroup A historically dominated the African meningitis belt but has declined markedly following introduction of the MenA conjugate vaccine.
  • Clinical presentation is similar across serogroups, rapid-onset meningitis and/or septicaemia, but the age distribution and outbreak patterns differ.

Summary

  • The MenB vaccine elicits a T-dependent, protein-specific immune response leading to production of bactericidal antibodies that neutralise complement evasion mechanisms of Neisseria meningitidis serogroup B.
  • In contrast, MenACWY conjugate vaccines target capsular polysaccharides, inducing robust antibody and memory responses against those serogroups.
  • The distinct capsule chemistry of serogroup B necessitated a novel, protein-based vaccine design, reflecting fundamental immunochemical and epidemiological differences between MenB and other meningococcal serogroups.

This integrated understanding underpins current vaccination strategies and ongoing surveillance to monitor antigenic variation and vaccine effectiveness against invasive meningococcal disease.

3. Single-dose oral ciprofloxacin prophylaxis as a response to a meningococcal meningitis epidemic in the African meningitis belt

Coldiron ME et al., PLoS Medicine, 2018 Trial registration: ClinicalTrials.gov NCT02724046 https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002593

Validated and Provable Methods of Detection and Measurement

Study design and setting:

  • A three-arm, open-label, cluster-randomised trial conducted during a 2017 Neisseria meningitidis serogroup C outbreak in Madarounfa District, Niger.
  • Clusters comprised villages meeting the WHO epidemic threshold (>10 suspected cases per 100,000 per week).
  • Interventions:
    • Standard care (control)
    • Household prophylaxis: single-dose oral ciprofloxacin (500 mg equivalent) to household contacts within 24 h of case notification
    • Village-wide prophylaxis: single-dose ciprofloxacin to all residents within 72 h of first case notification

Case detection and surveillance:

  • Passive health‑facility surveillance following WHO standard case definitions for suspected meningitis.
  • Confirmed cases identified via PCR testing of cerebrospinal fluid (CSF) at the national reference laboratory (CERMES, Niamey).
  • Attack rate (AR) defined as number of suspected cases per 100,000 population after village inclusion; index cases excluded.
  • Statistical analysis used cluster‑level log‑transformed ARs, t tests, and Poisson regression with overdispersion correction.

Antimicrobial resistance sub‑study:

  • 20 villages (10 control, 10 village‑wide prophylaxis) sampled for faecal carriage of ciprofloxacin‑resistant and extended‑spectrum β‑lactamase (ESBL), producing Enterobacteriaceae.
  • Stool samples cultured on MacConkey agar with 1 mg/L ciprofloxacin and/or cefotaxime.
  • Resistance confirmed by E‑test and synergy testing; 10% of isolates verified by MALDI‑TOF mass spectrometry and molecular methods at a reference laboratory (Université Paris Diderot).
  • Antimicrobial susceptibility interpreted per European Committee on Antimicrobial Susceptibility Testing (EUCAST) standards.

Key Findings (Quantitative and Qualitative)

Population and coverage:

  • 49 villages (71,308 residents): 17 control, 17 household prophylaxis, 15 village‑wide prophylaxis.
  • Median ciprofloxacin coverage: 77% (IQR 75–81%) in village‑wide arm; 4% (IQR 2–6%) in household arm.
  • Mean interval from inclusion to distribution: 2.4 days.

Primary outcome & attack rates:

Study arm AR per 100,000 Adjusted AR ratio (95% CI) vs control  p‑value 
Control  451   –   – 
Household prophylaxis  386   0.94 (0.52–1.73)   0.85 
Village‑wide prophylaxis  190   0.40 (0.19–0.87)   0.022 
  • Village‑wide prophylaxis reduced overall attack rate by approximately 60%.
  • Household prophylaxis conferred no statistically significant community‑level protection.
  • Individual‑level protective effectiveness of ciprofloxacin (any recipient vs no prophylaxis): 82% (95% CI 67–90%, p < 0.001).
  • No serious adverse events reported.
  • Intracluster correlation coefficient (ICC) = 0.00258, indicating minimal cluster dependency.

Confirmed microbiological results:

  • 74 CSF samples analysed by PCR; 28 (38%) positive for N. meningitidis C, 2 (3%) for Streptococcus pneumoniae.
  • Among post‑inclusion cases, 0 NmC‑positive results in the village‑wide arm (likely due to small sample size).

Antimicrobial resistance findings:

  • Baseline faecal carriage of ciprofloxacin‑resistant Enterobacteriaceae: 95%.
  • ESBL‑producing Enterobacteriaceae: > 90%.
  • No significant post‑intervention change in resistance prevalence detected.
  • Laboratory quality‑control concordance: 98%.

Operational outcomes:

  • Rapid, directly observed administration feasible at village scale.
  • Health communication and logistics were effectively integrated into existing epidemic response frameworks.

Relevance and Application to the UK Context (MelB Outbreak)

Translational relevance:

  • The study demonstrates that a single directly observed oral ciprofloxacin dose can rapidly reduce community transmission of meningococcal disease when deployed within 72 hours of case detection.
  • The cluster‑randomised design provides high internal validity for evaluating community‑level intervention effects under epidemic conditions.

Application to UK MelB outbreak response:

  • Enhanced surveillance and early detection:

    • The Niger model relied on WHO‑defined epidemic thresholds and rapid case notification.
    • In the UK, leveraging real‑time laboratory and genomic surveillance (e.g., Meningococcal Reference Unit data) could trigger targeted chemoprophylaxis at institutional or local‑network level before widespread dissemination.

  • Prophylaxis strategy:

    • Current UK guidance restricts antibiotic prophylaxis to close contacts of confirmed cases.
    • Evidence from this trial suggests that, during clusters or micro‑outbreaks (e.g., in schools or university residences), extending prophylaxis to a wider contact group may substantially reduce secondary transmission.
    • Directly observed administration ensures adherence and limits inappropriate dosing.

  • Antimicrobial resistance considerations:

    • Baseline resistance in Niger was exceptionally high; comparable surveillance in the UK indicates much lower ciprofloxacin resistance among enteric flora.
    • Nonetheless, systematic monitoring of resistance trends must accompany any expanded use of ciprofloxacin, ideally via coordinated national antimicrobial stewardship frameworks.

  • Feasibility and logistics:

    • The Niger study confirmed the operational practicality of mass single‑dose administration without cold‑chain requirements.
    • In the UK, this could support rapid deployment in institutional settings with minimal infrastructure.

  • Public health integration:

    • The finding that household prophylaxis alone did not reduce community attack rates underscores the need for proportionate, population‑level interventions within defined epidemiological clusters.
    • Incorporating ciprofloxacin mass prophylaxis into MelB outbreak response protocols would require rapid ethical and clinical governance review, backed by real‑time microbiological confirmation and resistance surveillance.

Key Lessons for Policymakers and Clinicians

  • Evidence base: Village‑wide, single‑dose ciprofloxacin prophylaxis yielded a statistically significant 60% reduction in attack rate (AR ratio 0.40; 95% CI 0.19–0.87).
  • Safety: No adverse events observed; method operationally feasible and rapidly deployable.
  • Limitations: Limited number of PCR‑confirmed cases; high baseline resistance context; rural setting.
  • Policy implication: In resource‑rich settings with robust laboratory capacity and lower resistance prevalence, targeted community‑level prophylaxis could be evaluated as an adjunct to vaccination and contact tracing during meningococcal outbreaks such as MelB.

In summary:

Validated surveillance and microbiological methods confirm that directly observed, single‑dose oral ciprofloxacin administered community‑wide can significantly reduce meningococcal attack rates without measurable short‑term increase in antimicrobial resistance. Adaptation of this approach for the UK MelB outbreak would require context‑specific risk assessment, integration with existing chemoprophylaxis guidelines, and rigorous resistance monitoring to ensure public health benefit without compromising antimicrobial stewardship.

Conclusion

This document has examined three interrelated parts. The first part provided an in‑depth overview of meningitis B, its aetiology, transmission, clinical features, diagnostic methods, treatment, prevention, and prognosis.

The second part explained the immunological mechanism of the MenB vaccine and delineated key biological and clinical contrasts between serogroup B and other meningococcal serogroups (A, C, W, Y).

The third part reviewed the Coldiron et al. (2018) study on single‑dose oral ciprofloxacin prophylaxis, evaluating its validated methodology, findings, and potential applicability to UK meningococcal outbreak management.

Together, these three sections emphasise the continuing importance of early recognition and treatment of meningitis B, the distinctive immunological challenges informing vaccine design, and the translational value of evidence‑based prophylactic strategies for effective public‑health intervention.

References

Harrison, L. H., Trotter, C. L., & Ramsay, M. E. (2009). Global epidemiology of meningococcal disease. Vaccine, 27(Suppl 2), B51–B63. https://doi.org/10.1016/j.vaccine.2009.04.063

Pizza, M., et al. (2000). Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science, 287(5459), 1816–1820. https://doi.org/10.1126/science.287.5459.1816

Stephens, D. S., Greenwood, B., & Brandtzaeg, P. (2007). Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. The Lancet, 369(9580), 2196–2210. https://doi.org/10.1016/S0140-6736(07)61016-2

Public Health Agency Guidelines:

World Health Organization (WHO) (2023). Meningococcal meningitis: WHO fact sheet. https://www.who.int/news-room/fact-sheets/detail/meningococcal-meningitis

Centers for Disease Control and Prevention (CDC) (2024). Meningococcal disease: CDC overview. https://www.cdc.gov/meningococcal/

Public Health England (PHE) (2020). Immunisation against infectious disease: Chapter 22 – Meningococcal. https://www.gov.uk/government/publications/meningococcal-the-green-book-chapter-22

(Note: The above reference is widely known as the UK’s “Green Book” chapter on meningococcal disease. The UK’s Green Book chapters are technically hosted under GOV.UK, and while originally published by PHE, they are now maintained by the UK Health Security Agency [UKHSA].)